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ABSTRACT 
Objective: Left ventricular (LV) hypertrophy involves numerous structural adaptations that may lead to ventricular dysfunction and eventually, 
heart failure. Particular emphasis is placed on the molecular mechanisms that govern the development of hypertrophy and may lead to maladaptive 
structural changes resulting in adverse cardiac events. This study investigates the effectiveness of Valsartan (Val) which is an angiotensinII receptor 
antagonist and Aliskiren (Ali) which is a direct rennin inhibitor in the treatment of cardiac remodeling resulted from renovascular hypertension, 
particularly left ventricular hypertrophy, and to address the molecular mechanisms underlying them.  
Methods: 24 male albino rats were randomly divided into 4 main groups (n=6 each), normal control rats (N), hypertensive control rats (HC), Val 
treated hypertensive rats (Val, 8 mg/kg/day orally) and Ali treated hypertensive rats (Ali, 25 mg/kg/day orally).  
Results: At the end of 4 weeks HC rats showed enhanced hypertrophic response (higher heart weight/body weight ratio) and dyslipidemia (lower 
high density lipoprotein "HDL-c" and higher triacyl glycerol "TAG") and a significant deletion of antioxidant enzymes in comparison with N group. 
The β myosin heavy chain "βMHC", regulator of calcineurin-1 "RCAN1", nuclear factor kappa B "NFκB" and inducible nitric oxide synthase "iNOS" 
was markedly elevated. While, α myosin heavy chain "αMHC" was markedly decreased as compared with N group. On the other hand Val treated 
hypertensive rats and Ali treated hypertensive rats showed a significant decrease in heart weight/body weight ratio, improved lipogram pattern 
and higher levels of antioxidant enzymes. While, cardiac β-MHC, RCAN-1, NFκB and iNOS were significantly decreased as compared with HC group. 
Both Val treated hypertensive rats and Ali treated hypertensive rats showed a significant increase in α-MHC, compared with HC group  
Conclusion: The results reported in this study suggested that chronic untreated hypertension induced a pathological hypertrophy. Administration 
of the Val or Ali individually exerted beneficial effects regarding the improved lipogram pattern and anti-oxidant enzymes levels, as well as cardiac 
hypertrophy and highlights the role of Val and Ali as a promising therapeutic strategy for hypertension and LV hypertrophy. 
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INTRODUCTION 
The presence of left ventricular (LV) hypertrophy is an independent 
risk factor for future cardiac events and all cause mortality [1]. 
Clinical and hermodynamic stimuli to LV hypertrophy induced not 
only an increase in cardiac mass and wall thickness, but also a 
fundamental reconfiguration of the protein, cellular and molecular 
components of the myocardium [2]. 
Early in heart failure, renin-aldosterone-angiotensin (RAAS) system 
is activated as a compensatory mechanism. With the progression of 
the disease, it assumes a detrimental role, responsible for increased 
preload and afterload which are the hallmarks of clinical heart 
failure syndrome [3]. Activation of the RAAS occurs following the 
release of renin from juxta glomerular apparatus within the kidney. 
Renin cleaves the circulating angiotensinogen to inactive 
angiotensin I (Ang I); that is converted to the biologically active 
peptide Ang II by the angiotensin converting enzyme (ACE) [4]. 
Angiotensin II which is a vasoconstrictor binds with Ang II typeI 
(AT1) receptors in the smooth muscle cells of the peripheral blood 
vessels causing vasoconstriction and consequently, increases the 
blood pressure (BP). Activation of AT1 receptors by Ang II also 
stimulates the release of aldosterone from the adrenal gland, which 
promotes retention of sodium and water along the nephron leading 
to further increasing in BP [5]. In pathologic conditions, the RAAS 
system could chronically activated resulting in hypertension and 
ultimately end-organ damage [6]. 
Increasing evidence has linked the RAAS with the associated risk 
factors, including obesity, hypertension [7], dyslipidemia [8] and 
oxidative stress [9]. The pharmacological inhibition of the RAAS 
could be achieved through three different basic mechanisms. The 
first mechanism is through inhibition of AngI generation from 
angiotensinogen by direct renin inhibitors. The second mechanism is 
through inhibition of AngII generation from Ang I by ACE inhibitors. 
The third mechanism is through direct inhibition of the action of 
AngII at receptor level by AngII receptor blockers (ARBs) [10]. 
At the molecular level, pathological stress induces multiple changes, 
including genetic reprogramming which is mediated by increased 
expression of a ''hypertrophic gene program". These genes include 
atrial natriuretic pepide, brain natriuretic peptide, β-myosin heavy 
chain (MHC) and the α skeletal muscle iso form of actin [11]. The 
changes in gene expression result in substantial phenotypic changes 
in size, contractility, metabolic state, and electric conductance. The 
re-expression of fetal genes is an important molecular indicator of 
pathological hypertrophy [12]. 
One potential focal regulator of cardiomyocyte hypertrophy that also 
responds to altered calcium handling is the calmodulin-activated 
serine/threonine protein phosphatase, calcineurin (CN). Once 
activated, CN mediates the hypertrophic response through its 
downstream transcriptional factor of activated T cells, (NFATs). The 
NFATs directly dephosphorylated by CN resulting in nuclear 
translocation. The previous studies have convincingly demonstrated 
the sufficiency of calcineurin to mediate cardiac hypertrophy and 
progressive heart failure [13]. Regulator of calcineurin 1 (RCAN1), a 
protein encoded by one of the target genes of NFAT binds to and 
inhibits calcineurin [14]. Vega and colleagues [15] suggested a dual 
role of RCAN1 in the development of cardiac hypertrophy. 
Valsartan (Val) belongs to the family of AngiotensinII receptor 
blockers (ARBs) and possesses about 20,000 fold greater affinity for 
AT1 than for the AT 2 receptor [16]. This action leads to reduction in 
BP as well as the decrease in vascular smooth muscle contraction 
[17]. In addition blockage of AT1 receptor by valsartan leads to 
increase in local Ang II concentration that stimulates the unblocked 
AT2 receptor. The increase in AT2 receptor stimulation causes 
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vasodiltation through local production of bradykinin that increases 
the production of nitric oxide (NO) and cyclic guanosine 3’-5’-
monophosphate providing protection against vascular dysfunction 
[18]. 
Aliskiren (Ali) inhibits the RAAS at the rate-limiting step by reducing 
plasma renin activity and thereby prevents the formation of Ang I 
and Ang II [19]. Renin and prorenin play key roles in cardiovascular 
physiology, but when in excess, contribute in the pathogenesis of 
many cardiovascular and renal abnormalities. Both renin and 
prorenin bind to the prorenin receptors with equal affinities and 
activate mitogen-activated protein kinase, leading to cell 
proliferation and to upregulation of profibrotic gene expression that 
result in pathological hypertrophy [20]. 
The overall aim of this study is to provide insights into the 
effectiveness of Val and Ali in modulating cardiac complications 
associated with renovascular hypertension. 
MATERIALS AND METHODS 
Experimental animals 
Male Wister albino rats, weighing 250±20 g, were purchased from 
The Egyptian Organization for Biological Products and Vaccines, 
Cairo, Egypt. The rats were housed in stainless steel wire-bottomed 
cages and exposed to 12 h light/dark cycle in the animal care facility 
at Faculty of Pharmacy, Zagazig University. The room temperature 
and humidity were maintained automatically at 25PοPC±2PοPC and 65% 
to 69%, respectively. The rats were fed rodent chow and allowed 
free access to drinking water. 
All the experimental procedures were conducted in accordance with 
the guidelines of the National Institutes of Health for animal 
research. The experimental protocol was approved by the 
Institutional Laboratory Animal Care and Use Committee of Faculty 
of Pharmacy, Zagazig University. 
Experimental design 
One week after acclimization, hypertension was induced, as 
previously reported [21]. Briefly, a short segment of the left renal 
artery was isolated by blunt dissection and standard silver clip was 
placed around the renal artery. Rats were randomly divided into 4 
main groups (n=6 each): normal control rats (N), hypertensive 
control rats (HC), Val treated hypertensive rats (8 mg/kg/day orally) 
and Ali treated hypertensive rats (25 mg/kg/day orally) [22]. Both 
Val and Ali were dissolved in distilled water and given for four 
weeks. 
Measurement of blood pressure 
At the end of the treatment period, rats were anaesthetized using 
tribromoethanol (100 mg/kg, IP), Bp was determined [23]. Briefly, 
the common carotid artery was cannulated. The cannula was 
connected to a Bp transducer (TP-200T; Nihon Kohden Co, Tokyo, 
Japan) coupled to a polygraph (AP-611G; Nihon Kohden Co). Mean 
arterial blood pressure (MAP) was calculated according to the 
formula: MAP= ¼ Diastolic BP+1/3 (Systolic BP-Diastolic BP) [24]. 
Measurement of biochemical parameters 
At the end of the experiment, animals were fasted overnight; blood 
was collected via retro-orbital bleeding in dry centrifuge tube and 
centrifuged at 3000xg for 15 minutes. Serum was collected, divided 
into aliquots and stored at-20PοPC for the determination of high 
density lipoprotein cholesterol (HDL-c)  [25] and triacyl glycerol 
(TAG) [26], using commercially available kits (Spinreact, Sant Esteve 
de Bas, Spain). 
After blood collection, rats were killed by decapitation. Hearts were 
removed, washed with 0.9% NaCl, excised and weighed. The heart 
weight was normalized by body weight. Part of the harvested organs 
was quickly frozen in liquid nitrogen (-170PoPC) for 5 minutes then 
stored at-20 PoPC and processed for analysis of superoxide dismutase 
(SOD), glutathione peroxidase (GPX), α and β myosin heavy chain (α, 
β MHC) and regulator of calcineurin-1 (RCAN1) gene expressions by 
Reverse Transcription-Polymerase Chain Reaction (PCR)  [27] 
(table.1). 
 
Table 1: Primer sequences for the studied genes 
Gene Primer sequence 
SOD  Forward primer: 5’-GGTGGTCCACGAGAAACAAG-3’ 
Reverse primer: 5’-CAATCACACCACAAGCCAAG-3’ 
GPX Forward primer: 5’-TGCAATCAGTTCGGACATC-3’ 
Reverse primer: 5’-CACCTCGCACTTCTCAAACA-3’  
αMHC Forward primer: 5’-CGAGTCCCAGGTCAACAAG-3’ 
Reverse primer: 5’-AGGCTCTTTCTGCTGGACC-3’ 
βMHC Forward primer: 5'-CATCCCCAATGAGACGAAG-3' 
Reverse primer: 5'-AGGCTCTTTCTGCTGGACA-3' 
RCAN-1 Forward primer: 5’-TCGACTGCGTAGATGGAGG-3’ 
Reverse primer: 5’-TGGTGTCCTTGTCATATGTTCTG-3’ 
Abbreviations: SOD, superoxide dismutase; GPx, glutathione 
peroxidase; αMHC, alpha myosin heavy chain; βMHC, βeta myosin 
heavy chain; RCAN-1, regulator of calcineurin-1.  
 
Histopathological and immunohistochemical assessment 
The harvested hearts were dissected into right ventricle and left 
ventricle, including the septum. The left ventricles were fixed in 10% 
buffered formalin, dehydrated, embedded in paraffin and then sliced 
into 5 mm thick sections. After being de paraffinized, slices were 
stained by hematoxylin and eosin (H&E) stain [28]. They were 
analyzed using an image analyzer computer system (Leica Qwin 500, 
UK) in order to determine the myocyte cross-sectional area and the 
area percentage of interstitial fibrosis. Immunohistochemical testing 
was done [29] for determination of nuclear factor kappa B (NFκB) 
and inducible nitric oxide synthase (iNOS) antibodies.  
Statistical analysis 
All data were expressed as means±standard deviation. Results were 
analyzed by analysis of variance ([ANOVA]; 1-way) followed by Tukey 
post hoc test, P<0.05 was considered significant. Statistical analysis 
was performed using SPSS (version, 16 SPSS Inc, Chicago, USA). 
RESULTS 
Blood pressure, heart weight/body weight ratio 
As shown in table 2, the MAP tended to increase and cardiac 
hypertrophy was more evident in HC group, relative to N rats. 
Aliskiren and Val treatment significantly attenuated the elevation of 
MAP and cardiac hypertrophy compared to HC group (P* P*P<0.001).
  
Table 2: Effect of Val and Ali administration on MAP and heart/body weight ratio in hypertensive rats 
 Normal rats (N) Hypertensive rats 
HC Val  Ali  
MAP (mmHg) 90±3.9 128.3±12.5* 93.5±5P# 98.1±2.3P# 
heart/ body weight ratio 4.3 x10P-3P±0.3 6.9 x10P-3P±0.3P* 3.8 x10P-3P±0.5P# 3.4 x10P-3P±0.3P# 
Mean arterial blood pressure (MAP) and heart/body weight ratio were determined in normal rats (N), hypertensive control rats (HC) and 
hypertensive rats receiving either Val (8 mg/kg) or Ali (25 mg/kg) orally and daily for 4 weeks. Results were expressed as mean±SD and n=6 
rats/group.P⃰* P ˂0.001 as compared to N groups and P# P ˂0.001 as compared to HC 
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Serum lipid profile 
Hypertensive rats demonstrated significant (*
 
P<0.05) decrease in 
serum HDL-c, associated with significant increase in TAG level in 
comparison with N group. Hypertensive rats received Val or Ali 
showed a remarkable improvement in their lipogram pattern in 
comparison with HC group (**P<0.001), (fig. 1). 
 
Fig. 1: Effect of Val and Ali administration on serum HDL-c and 
TAG. Results are expressed as mean±SD, n= (6), (*
 
P<0.05). 
*significantly different from (N) group. # significantly different 
from (HC) group 
Cardiac SOD, GPx, α, β-MHC and RCAN-1, gene expression 
Cardiac SOD, GPx and α-MHC, and were significantly decreased in HC 
group, while cardiac β-MHC and RCAN-1 gene expression were 
significantly increase, compared with N group.  
On the other hand rats receiving either Val or Ali had elevated 
SOD, GPx and α-MHC as well as the reduced level of β-MHC and 





Fig. 2: representative profiles of agarose gel electrophoresis 
showing PCR products of cardiac SOD, GPx,α, β MHC, RCAN-1 
mRNA genes and control gene (β-actin in all groups (n=6). Lane 
m: 100 bp. DNA ladder 
 
Histopathological and immunohistochemical study  
Light microscope examination of heart sections of HC group showed 
marked histological changes, where cardiac muscle appeared 
hypertrophied, fragmented and degenerated. In addition, blood 
vessels appeared congested as compared with N group.  
Treatment of hypertensive rats with Val or Ali resulted in moderate 
improvement of ventricular tissues. Most of cardiac muscle fibers 
appeared normal in shape. However, some of them were 
hypertrophied and degenerated (fig. 3). 
 
Fig. 3: A photomicrograph of a section in the cardiac muscle of 
normal (N), hypertensive control (HC), valsartan (Val) and 
aliskiren (Ali) treated rats (H&E X 400) 
 
 
Fig. 4: Immunohistochemical analysis of cardiac muscle of 
normal (N), hypertensive control (HC), valsartan (Val) and 
aliskiren (Ali) treated rats by using NFκB antibodies, (arrow: 
cardiac muscle nucleus). (NFκB X 400) 
 
 
Fig. 5: Immunohistochemical analysis of cardiac muscle of 
normal (N), hypertensive control (HC), valsartan (Val) and 
aliskiren (Ali) treated rats by using iNOS antibodies, (arrow: 
cardiac muscle nucleus). (iNOS X 400) 
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Immunohistochemical examination of the cardiac muscle of HC by 
using NFκB and iNOS antibodies revealed the remarkable increase in 
their activity as indicated by strong brown positive cytoplasmic 
reaction, in comparison with N rats. Meanwhile, Val or Ali treated 
rats showed remarkable reduction in their levels as indicated by 
moderate cytoplasmic reaction (faint stain), in comparison with HC 
group (fig. 4 and fig. 5). 
CORRELATION 
Using the combined results from all groups, we illustrated that MAP 
was positively correlated with heart weight/body weight ratio 
(r=0.843), and TAG (r=0.798), βMHC (r=0.730) and RCAN-1 
(r=0.859). Meanwhile the same parameter was negatively correlated 
with HDL-c (r=-0.602), SOD (r=-0.592), GPx (r=-0.646) and αMHC 
(r=-652) gene expression, (**
On the other hand, heart weight/body weight ratio was positively 
correlated TAG (r=0.885), βMHC (r=0.572) and RCAN-1 (r=0.762). 
On the other hand, it negatively correlated with HDL-c (r=-0.775), 





The current experimental hypertensive rats developed dyslipidemia 
as manifested by a significant decrease in HDL-c and elevation in 
TAG levels, accompanied by significant deletion of SOD and GPX 
enzymes. While, hypertension induced hypertrophy develops a 
myocyte phenotypic modulation, indicated by decreasing α MHC and 
increasing β MHC and RCAN-1gene expression compared with N 
rats.  
Previous study [30] suggested that elevated (AngII) via activation of 
the RAAS affects glucose and lipid metabolism through multiple 
direct and indirect mechanisms. These mechanisms include 
impairing of the first phase of glucose-stimulated insulin secretion 
and biosynthesis and promoting β cell apoptosis [31]. This leads to 
attenuated activity of lipoprotein lipase subsequent to defects in 
insulin secretion and/or action and reduction of chylomicrons and 
VLDL-c clearance from the circulation [32]. Furthermore, the activity 
of cholesteryl ester transfer protein is increased, which is 
responsible for the transfer of TAG from VLDL-c, IDL-c or LDL-c to 
HDL-c in an exchange for cholesterol ester. This in turn contributes 
to low HDL-c levels and high levels of TAG-rich lipoproteins 
(chylomicrons and VLDL-c) [33]. 
A large body of evidence supports a crucial role for reactive oxygen 
species (ROS) production, particularly from nicotinamide adenine 
dinucleotide phosphate hydrogen (NAD(P)H) oxidase, an enzyme 
present in vascular wall cells. In vascular injury which characterizes 
the hypertension, Ang II represents one of the major vasoactive 
peptides, together with cytokines and growth factors, involved in the 
regulation and activation of NAD(P)H oxidase, which is widely 
recognized as the primary source of superoxide anion (OR2RP.−P) [34]. 
Experimental reports documented that Ang II may exert such effects via 
AT1receptor. Of note, ROS may regulate AT1 receptor gene expression, 
which in turn modulates ROS generation, thus perpetuating a vicious 
circle [35]. The decrease in the antioxidant enzymes could be due to their 
inactivations as the result of a continuous exposure to hydrogen 
peroxide, hydrogen peroxynitrite and other free radicals [36]. Studies 
have shown that this reduction could also be due to the down regulation 
of their gene expressions [37]. 
It was reported that MHCs are the ‘molecular motor’ of the heart, and 
contractile properties heavily depend on the composition of MHC 
proteins. A down-regulation of α-MHC and an up-regulation of β-MHC 
are observed in experimental models of cardiac hypertrophy as well as 
in patient with chronic heart failure. This shift in isoform composition 
results in a reduction of contractile over-velocity and reduced energy 
expenditure [38]. The β-MHC is characterized by lower adenosine 
triphosphatase activity and lower filament sliding velocity, but can 
generate cross-bridge force with a higher economy of energy 
consumption than α-MHC. This suggests that a shift from α to β-MHC 
might be an adaptive response in order to preserve energy [30]. 
The calcium-calmodulin-activated phosphatase, calcineurin (CN) 
and its downstream transcriptional effector nuclear factor of 
activated T-cells, NFAT have been implicated as critical transducers 
of the hypertrophic response that uniquely link alterations in 
intracellular calcium handling in a myocyte to the hypertrophic 
growth response [40]. An approach used to genetically inhibit CN 
involved transgenic over expression of the CN inhibitory protein 
RCAN-1which is highly enriched in cardiac and slow skeletal muscle 
[41]. 
Interestingly, RCAN1 plays a critical role in cardiac hypertrophy. 
RCAN1 over expression blocks pathological hypertrophy and heart 
failure associated with increased load induced by hypertension or 
aortic stenosis. The RCAN1 expression is transcriptionally regulated 
by CN and NFAT, such that the third intron of the human RCAN1 
gene contains a cluster of 15 consensus NFAT binding sites, making 
RCAN1 the first known feedback regulator of this pathway [42]. 
Immunohistochemical assessement revealed that hypertension and 
the induced cardiac hypertrophy promotes NFκB and iNOS levels 
induction in adult rat cardiomyocytes, in harmony with previous 
litratures [43, 44]. Hypertrophic mechanical stretch promotes 
vascular endothelial growth factor secretion via activation of the 
NFκB pathway in adult rat cardiomyocytes. Activation of the NFκB 
pathway is dependent upon the degradation of the inhibitory 
protein and subsequent translocation of the NFκB complex to the 
nucleus where it activates gene transcription. The NFκB pathway is 
involved in regulating the immediate early genes and is required for 
cardiomyocyte hypertrophic growth by binding to the two NFκB 
recognition sites in the vascular endothelial growth factor promoter 
[45]. 
Nitric oxide production via iNOS plays an important role in 
modulating cardiac function after moderate aortic banding that 
mimics long-term hypertension in humans [46]. The expression of 
iNOS in cardiomyocytes only increases following certain events such 
as increased cardiomyocyte stretch secondary to protein kinase and 
through positive feedback from increased NO concentration [47]. In 
such cases, iNOS appears to contribute to myocardial dysfunction 
and alters the myocardial response to β-adrenergic stimulation [48]. 
In failing hearts increased iNOS expression is associated with 
increased arginase II expression, but increased arginase II gene 
expression preceded that of iNOS, so arginase II competes with iNOS 
for arginine. With substrate limitation, iNOS may become uncoupled 
and produce OR2RP.-Pand contribute to contractile dysfunction and heart 
failure [49]. 
Our biochemical results were potentially confirmed by the 
histopathological ones, which demonstrated that cardiac muscle 
fibers of hypertensive rats appeared hypertrophied, fragmented and 
degenerated. In addition, blood vessels appeared congested. These 
data are in consistence with previous study [50]. 
The current study demonstrated that hypertensive rats treated with 
Val exhibited an increase in their HDL-c accompanied by a 
significant decrease in TAG level, an elevation in SOD, GPx and α 
MHC and reduction in β MHC and RCAN-1 gene expressions 
compared with hypertensive rats. 
The lipid-lowering property of Val is possibly due to numerous 
different mechanisms. It is well known that ARBs have the potential 
to activate peroxisome proliferator-activated receptor gamma 
(PPARγ) which partially reduces TAG and LDL-C levels [51]. The 
PPARs act as anti-inflammatory transcription factors. Part of this 
anti-inflammatory regulation is mediated through negative 
interference between PPARs and nuclear factors such as NFκB [52]. 
On the other hand, Ang II increases lipid uptake in cells and lipid 
accumulation in the vessel wall, these changes were reversed by 
ARBs [53].  
Activation of AngII and AT1 receptor by hypertension stimulate NAD 
(P)H oxidase, resulting in the generation of OR2RP-. P in vascular cells and 
eventually, endothelial dysfunction. Valsartan significantly inhibit 
AngII activation of AT1 receptors [54].  
The Valsartan Heart Failure Trial (Val-HeFT) provided the first 
opportunity to examine the sustained reduction of plasma 
aldosterone level by Val [55]. Aldosterone activity is principally 
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controlled by Ang II and potassium and more weakly by 
adrenocorticotropic hormone and sodium. Angiotensin II and 
aldosterone may have interactions in myocardium, since Ang II 
enhances cardiac aldosterone synthesis. On the other hand, 
aldosterone increases AT-1 receptor mRNA and density and 
potentiates AngII-stimulated hypertrophy [56]. The AngII directly 
stimulates LV atrial natriuretic peptide via AT1 receptor 
independently of its hypertensive effect, this action is accompanied 
by a shift from αMHC to the fetal isoform βMHC [57]. We can 
hypothesis that Val actually reverses Ang II-aldosterone structural 
remodeling of the LV. 
Many complex signaling pathways are stimulated after binding of 
AngII to its cell surface receptors. One of the most important 
pathways is the CN-NFAT pathway and this pathway has a distinct 
role in cardiac hypertrophy. The inhibitory protein RCAN1is 
identified as a CN-sensitive AngII-activated gene. The lower mRNA 
expression of RCAN-1 gene in Val treated group may be attributed to 
the inhibitory action of ARBs on AngII binding to its receptors [58]. 
Immunohistochemical results demonstrated that Val cause a 
concomitant suppression of NFκB and iNOS, as compared to HC 
group.  
Previous explanation [59] recommended that Ang II may directly act 
on NAD (P)H oxidase which generates ROS that activate NFκB 
pathway. NFκB is a transcription factor binding specific sequences in 
the promoter regions of target genes thus inducing transcription of 
pro-inflammatory cytokines, chemokines, mediators of 
inflammation, immune receptors and adhesion molecules [60]. 
Angiotensin receptor-1 blockade decreases TNFα which stimulates 
transcription and expression of iNOS and this may explain the 
decrease in iNOS level after AT1 receptor blockade [61]. 
The current study demonstrated that rats administered Ali exhibited 
an improvement in HDL-c level accompanied with an attenuation in 
TAG level, elevation in antioxidant enzymes levels, as well as 
attenuated LV hypertrophic gene programming compared with HC 
rats.  
Aliskiren can modify intra-cellular distribution of fatty-acid and 
glucose transporters which dynamically traffic between subcellular 
compartments and the plasma membrane in cardiomyocytes and 
increasing uptake of glucose and fatty acids [62]. The rate of lipolysis 
is determined predominantly by insulin and B-adrenoceptors, both 
of which are negatively regulated by RAAS over-activation in an Ang 
II-dependent manner [63]. 
Additionaly, Ang II can interfere with lipid metabolism as evidenced 
by its ability to reduce HDL-c and increase cholesterol storage [64]. 
The inhibition of Ang II production by Ali may be effective in 
reducing hyperlipidemia induced by AngII over-expression [65]. 
The possible protective effect of Ali could be based upon its anti-
hypertensive effect that is associated with inhibition of renin and 
hence there is an inhibition of AngII production. It is well known that 
Ang II activates NAD (P)H oxidase, enhances the expression of 
NAD(P)Hsubunits and stimulates ROS production [66]. 
It is well known that AngII directly stimulates LV hypertrophy gene 
expression, via AT1 receptor independently of its hypertensive effect 
[67], this action is accompanied by a shift from α-MHC to β-MHC 
[57]. Therefore, the mechanism underlying the greater suppression 
of β-MHC and enhancement of α-MHC gene expression, may be 
explained by more potent inhibition of Ang II–production by Ali 
monotherapy [68]. 
On the other hand, Ang II induces pathological artery wall 
remodeling via CN and RCAN1. Renin is the rate-limiting step in the 
generation of Ang II. Therefore, the mechanism underlying the 
greater suppression of β-MHC and RCAN-1 and enhancement of α-
MHC gene expression may be explained by more potent inhibition of 
Ang II–production by Ali monotherapy. 
Immunohistochemical study indicated that rats treated with Ali 
showed significant decrease in NF-κB and iNOS levels. 
Renin inhibition prevents Ang II promoted activation of NF-κB 
pathway [30] and similar transcriptional and posttranscriptional 
mechanisms interrelated in complex intracellular cross-talk 
mechanisms. These include activation of phospholipase C and 
protein kinase C, leading to NAD (P)H oxidase stimulation and 
enhanced ROS formation [69]. 
The relationship between NO and local RAAS is complex and the 
mechanisms leading to the production of NO by Ang II are 
controversial. Angiotensin II stimulates inositol phosphate 
production and increases intracellular calcium concentration. This 
increase in intracellular calcium might be responsible for the 
activation of iNOS exerts deleterious effects by increasing 
peroxidative damage of cell membranes and apoptotic cell death 
[70]. 
The latter findings are reinforced by the histopathological study 
where Val and Ali resulted in a moderate improvement of the 
architecture of ventricular tissues, where most of cardiac muscle 
fibers appeared normal in shape. However, some of them were still 
hypertrophied and degenerated. Previous studies [71, 72] showed 
nearly similar results.  
CONCLUSION 
In conclusion, the present study provides an experimental rationale 
for the use of Val and Ali in the treatment of hypertension and 
related LV hypertrophy indicated by the substantial decrease in 
heart/bodyweight ratio. The beneficial effects of Val and Ali could be 
a consequence of an improvement in the lipid profile which induces 
cardioprotection and an enhancement of antioxidant enzymes. In-
depth understanding of molecular mechanisms of cardiac 
hypertrophy will finally provide valuable information in the design 
of novel treatment strategies that promote protective signaling 
pathways and prevent maladaptive responses. It seems that Ali was 
as effective as Val in promoting LV mass regression and attenuating 
end-organ damage, independent of blood pressure lowering. 
Obviously, further large studies scale experimental and clinical is 
required to recommend and apply this potential therapeutic benefit. 
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